SUMMIT, N.J., May 03, 2018 (GLOBE NEWSWIRE) -- Engage Therapeutics, Inc., today announced dosing of the first patient in its multi-center, double-blind, randomized Phase 2b StATES (Staccato ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback